scholarly journals Serum Vitamin D and the Metabolic Syndrome Among Osteoporotic Postmenopausal Female Patients of a Family Practice Clinic in Jordan

2015 ◽  
Vol 24 (2) ◽  
pp. 245-250 ◽  
Author(s):  
Nada Yasein ◽  
Wejdan Shroukh ◽  
Razan Hijjawi
Diabetes Care ◽  
2010 ◽  
Vol 33 (4) ◽  
pp. 923-925 ◽  
Author(s):  
H. L. Gulseth ◽  
I. M. F. Gjelstad ◽  
A. C. Tierney ◽  
J. A. Lovegrove ◽  
C. Defoort ◽  
...  

Diabetes Care ◽  
2005 ◽  
Vol 28 (5) ◽  
pp. 1228-1230 ◽  
Author(s):  
E. S. Ford ◽  
U. A. Ajani ◽  
L. C. McGuire ◽  
S. Liu

2017 ◽  
Vol 64 (4) ◽  
pp. 300-304
Author(s):  
Ana Maria Alexandra Stănescu ◽  
◽  
Ioana Veronica Grăjdeanu ◽  
Gabriel Cristian Bejan ◽  
Mihaela Adela Iancu ◽  
...  

Aims. The rising global trend of metabolic syndrome cases has increased the problems associated with decreasing serum vitamin D levels and the likelihood of cutaneous involvement. This research was aimed at determining the prevalence of metabolic syndrome, the distribution of its components and correlation the between serum vitamin D levels and possible skin involvement in the patients. Materials and methods. The study of Romanian citizens was conducted between 2010 and 2017, involved mainly urban dwellers with a median age of 18. The parameters measured included physical examination and fasting blood tests. The criteria of the International Diabetes Federation (IDF) was used for the metabolic syndrome diagnosis. The serum 25 (OH) D levels were based on the laboratory reference values and the severity of psoriasis was calculated according to the BSA score. Results. The total number of participants in the study was 634, of which 36% were diagnosed with metabolic syndrome, with a 59% prevalence of females. The distribution of the components of the metabolic syndrome was: 100% increased waist circumference (mandatory component for diagnosis), hyperglycaemia 53.7%, low HDL cholesterol 44.9%, triglyceride increase 26.4%, high blood pressure 21.6%. Low serum vitamin D levels were found at 54.6%. Psoriasis showed 46.2% of all those with metabolic syndrome. Conclusion. After thorough analysis of the data, it can be concluded that there is a relationship between the presence of metabolic syndrome and serum vitamin D, the latter being mostly low in the studied group. The more the components of metabolic syndrome are present, the lower the vitamin D serum level. The presence of psoriasis can aggravate metabolic syndrome components and vitamin D serum decline. Further studies can determine whether serum vitamin D normalization can bring improvements in metabolic syndrome components.


2018 ◽  
Vol 2018 ◽  
pp. 1-6 ◽  
Author(s):  
Luz Adriana Sarmiento-Rubiano ◽  
José Armando Angarita Ruidiaz ◽  
Héctor Fernando Suarez Dávila ◽  
Alfonso Suarez Rodríguez ◽  
Roberto C. Rebolledo-Cobos ◽  
...  

Background. Previous evidence suggests that metabolic disorders in postmenopausal women could be related with low serum vitamin D levels. For example, vitamin D deficiency has been associated with increased risk factors for cardiovascular disease (CVD), mainly those related with metabolic syndrome.Objective. To assess the relationship between the serum vitamin D (25-OH-D) levels and the metabolic syndrome markers in postmenopausal women.Methods. This descriptive and cross-sectional study was conducted in 183 postmenopausal women of four municipalities from Colombian Caribbean. The serum 25-OH-D levels and the anthropometric and biochemical markers were assessed and correlated with metabolic syndrome.Results. The average value of serum vitamin D (25-OH-D) was 26.34 ± 9.08 ng/mL, and 69.95% of the women had vitamin D levels <30 ng/mL, of which 43.72% were with insufficiency (<30 to >20 ng/mL) and 26.23% with deficiency (<20 ng/mL). Of the evaluated women, the 81.42% seemed to have metabolic syndrome. Through the linear regression, one significant positive association was observed between the HDL cholesterol and the 25-OH-D levels (P=0.014).Conclusion. In the evaluated population in this study, vitamin D deficiency is related with low HDL cholesterol levels.


2019 ◽  
Vol 79 (03) ◽  
pp. 293-299
Author(s):  
Gurhan Guney ◽  
Bilge Sener-Simsek ◽  
Aytekin Tokmak ◽  
Aykan Yucel ◽  
Umran Buyukkagnici ◽  
...  

Abstract Introduction The aim of this study was to compare serum vitamin D and osteocalcin levels in non-osteoporotic postmenopausal women with and without metabolic syndrome and to analyze the relationship between serum vitamin D and osteocalcin levels and the relationships between these two factors and other clinical/biochemical parameters. Material and Method This cross-sectional study was carried out in 191 postmenopausal non-osteoporotic (T-score > − 2.5) women. Patients were divided into two groups according to the presence or absence of metabolic syndrome. Blood samples were obtained and evaluated for 25-hydroxyvitamin D, osteocalcin, insulin resistance (using a homeostatic model assessment of insulin resistance), glycosylated hemoglobin (HbA1c), calcium, phosphorus, deoxypyridinoline, thyroid-stimulating hormone, lipid profile, fasting insulin, fasting glucose and HbA1c levels. Demographic and laboratory parameters were recorded for each woman. Results Vitamin D was found to be lower in women with metabolic syndrome compared to controls (16.1 ± 11.2 vs. 20.4 ± 13.1 mg/dL; p = 0.013). Similarly, osteocalcin was found to be significantly lower in the metabolic syndrome group compared to the control group (4.2 ± 2.1 vs. 5.5 ± 3.0; p < 0.001). A significant positive correlation was observed between vitamin D and osteocalcin levels (r = 0.198; p = 0.008). There was an inverse correlation between vitamin D and some of the lipid parameters. However, osteocalcin levels were negatively correlated with C-reactive protein, insulin resistance, and HbA1c in both groups (p = 0.003, p = 0.001 and p = 0.048, respectively). Conclusion Vitamin D deficiency is common in postmenopausal women, even in women who are non-osteoporotic. Serum levels of vitamin D are significantly decreased in cases with metabolic syndrome. Vitamin D may directly improve serum lipid profiles and may indirectly decrease insulin resistance and subclinical systemic inflammation through the impact on the metabolic functions of osteocalcin.


2014 ◽  
Vol 2014 ◽  
pp. 1-9 ◽  
Author(s):  
Davide Francomano ◽  
Andrea Lenzi ◽  
Antonio Aversa

Metabolic and hormonal modifications after long-term testosterone (T) treatment have never been investigated. 20 hypogonadal men (mean T = 241 ng/dL–8.3 nmol/L) with metabolic syndrome (MS, mean age 58) were treated with T-undecanoate injections every 12 weeks for 60 months. 20 matched subjects in whom T was unaccepted or contraindicated served as controls. Primary endpoints were variations from baseline of metabolic and hormonal parameters. In T-group, significant reductions in waist circumference (−9.6±3.8 cm,P<0.0001), body weight (−15±2.8 Kg,P<0.0001), and glycosylated hemoglobin (−1.6 ± 0.5%,P<0.0001) occurred, along with improvements in insulin sensitivity (HOMA-I;−2.8 ± 0.6,P<0.0001), lipid profile (total/HDL-cholesterol ratio−2.9±1.5,P<0.0001), systolic and diastolic blood pressure (−23±10and−16±8mm Hg,P<0.0001, resp.), and neck and lumbar T-scores (+0.5±0.15 gr/cm2,P<0.0001;+0.7±0.8,P<0.0001, resp.). Also, serum vitamin D (+14.0±1.3 ng/mL,P<0.01), TSH (− 0.9±0.3 mUI/mL,P<0.01), GH (0.74±0.2 ng/mL,P<0.0001), and IGF1 (105±11 ng/mL,P<0.01) levels changed in T-group but not in controls. Normalization of T levels in men with MS improved obesity, glycemic control, blood pressure, lipid profile, and bone mineral density compared with controls. Amelioration in hormonal parameters, that is, vitamin D, growth hormone, and thyrotropin plasma levels, were reported.


2020 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Stephen W. Farrell ◽  
David Leonard ◽  
Carolyn E. Barlow ◽  
Benjamin L. Willis ◽  
Andjelka Pavlovic ◽  
...  

2021 ◽  
Vol 28 (1) ◽  
pp. E202113
Author(s):  
Sevil Karahan Yılmaz ◽  
Cuma Mertoğlu ◽  
Aylin Ayaz

Aim: This study is aimed to evaluate the relationship between serum vitamin D levels and metabolic syndrome in hemodialysis patients. Materials and Methods: This study was conducted with participation of 80 patients undergoing hemodialysis for more than 6 months three times a week, aged > 18 years. Their height, dry weight, waist circumference were measured. Biochemical parameters such as serum 25-hydroxyvitamin D, lipid profile, and fasting blood glucose were analyzed. Metabolic syndrome was defined using the National Cholesterol Education Program Adult Treatment Panel III criteria. Severe vitamin D deficiency, 25 (OH) vitamin D < 5 ng/ml; mild vitamin D deficiency, 25 (OH) vitamin D 5-15 ng/ml; vitamin D insufficiency, 25 (OH) vitamin D 16-30 ng/ml, and vitamin D sufficiency, 25 (OH) vitamin D > 30 ng/ml were categorized. Statistical analysis of the data was performed with the use of SPSS version 21.0. Results: 48.4% of hemodialysis patients were identified to have metabolic syndrome. According to the serum levels of vitamin D; 35.0% of patients had severe vitamin D deficiency, 37.4% of patients had mild vitamin D deficiency, 18.8% of patients had vitamin D insufficiency and 8.8% of patients had vitamin D sufficiency (> 30 ng/ml). Vitamin D insufficiency was significantly associated with metabolic syndrome and central obesity. Conclusions: Deficiency/insufficiency is observed in serum 25-hydroxyvitamin D levels in hemodialysis patients. Vitamin D insufficiency is associated with metabolic syndrome.


Endocrine ◽  
2012 ◽  
Vol 42 (3) ◽  
pp. 739-741 ◽  
Author(s):  
Tetsuyuki Yasuda ◽  
Yasuyuki Okamoto ◽  
Noboru Hamada ◽  
Kazuyuki Miyashita ◽  
Mitsuyoshi Takahara ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document